AR110371A1 - Formulación de comprimido farmacéutico - Google Patents

Formulación de comprimido farmacéutico

Info

Publication number
AR110371A1
AR110371A1 ARP170103512A ARP170103512A AR110371A1 AR 110371 A1 AR110371 A1 AR 110371A1 AR P170103512 A ARP170103512 A AR P170103512A AR P170103512 A ARP170103512 A AR P170103512A AR 110371 A1 AR110371 A1 AR 110371A1
Authority
AR
Argentina
Prior art keywords
heart failure
formulation
pharmaceutical tablets
hfref
hfpef
Prior art date
Application number
ARP170103512A
Other languages
English (en)
Inventor
Stroyer Anke Dr
Schwer Christine Dr
Pfeffer Michael Dr
Lobback Carmen Dr
Ide Katrin Dr
Serno Peter Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR110371A1 publication Critical patent/AR110371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación de comprimido farmacéutico que comprende 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etil-L-alanil-L-alaninato (neladenoson bialanato) en la forma de una de sus sales, en donde libera el ingrediente activo rápidamente, y a procesos para su producción, al uso de este como un medicamento, y al uso de este para la profilaxis y/o tratamiento de trastornos cardiovasculares, por ejemplo insuficiencia cardíaca crónica agravada, insuficiencia cardíaca con fracción de eyección del ventrículo izquierdo reducida o conservada (HFrEF o HFpEF), angina pectoris y lesión isquémica durante un síndrome coronario agudo.
ARP170103512A 2016-12-16 2017-12-14 Formulación de comprimido farmacéutico AR110371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16204750 2016-12-16

Publications (1)

Publication Number Publication Date
AR110371A1 true AR110371A1 (es) 2019-03-20

Family

ID=57614148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103512A AR110371A1 (es) 2016-12-16 2017-12-14 Formulación de comprimido farmacéutico

Country Status (4)

Country Link
AR (1) AR110371A1 (es)
TW (1) TW201836592A (es)
UY (1) UY37525A (es)
WO (1) WO2018108884A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
BR112017023852A2 (pt) 2015-05-06 2018-07-17 Bayer Pharma Aktiengesellschaft Processo para preparar monocloridrato de l- alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il] metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4- il]fenoxi}etil-l-alanila.

Also Published As

Publication number Publication date
UY37525A (es) 2018-06-29
TW201836592A (zh) 2018-10-16
WO2018108884A1 (de) 2018-06-21

Similar Documents

Publication Publication Date Title
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
CL2015000880A1 (es) Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto.
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
IN2014MU01042A (es)
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
JP2018503687A5 (es)
PT3544977T (pt) Um sal maleato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulações farmacêuticas, métodos de produção e suas utilizações para o tratamento de vírus herpes
BR112017028137A2 (pt) agente terapêutico para fibrose
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.
AR095220A1 (es) Conjunto para un dispositivo de administración de fármacos
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
AR110371A1 (es) Formulación de comprimido farmacéutico
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
MA42039A (fr) Procédé de préparation de monohydrochlorure de 2-{4-[2-({[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl}sulfanyl)-3,5-dicyan-6-(pyrrolidin-1-yl)pyridin-4-yl]phénoxy}éthyl-l-alanyl-l-alaninate
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
AR095194A1 (es) Conjunto para un dispositivo de administración de fármacos
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
MD3244889T2 (ro) Compoziţie farmaceutică pentru tratamentul micozei

Legal Events

Date Code Title Description
FB Suspension of granting procedure